These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27021205)

  • 1. Overview of elagolix for the treatment of endometriosis.
    Melis GB; Neri M; Corda V; Malune ME; Piras B; Pirarba S; Guerriero S; Orrù M; D'Alterio MN; Angioni S; Paoletti AM
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):581-8. PubMed ID: 27021205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of elagolix in the treatment of endometriosis.
    Perricos A; Wenzl R
    Expert Opin Pharmacother; 2017 Sep; 18(13):1391-1397. PubMed ID: 28737050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain.
    Ezzati M; Carr BR
    Womens Health (Lond); 2015 Jan; 11(1):19-28. PubMed ID: 25581052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature.
    Alessandro P; Luigi N; Felice S; Maria PA; Benedetto MG; Stefano A
    Arch Gynecol Obstet; 2017 Apr; 295(4):827-832. PubMed ID: 28255765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain.
    Barra F; Scala C; Ferrero S
    Drugs Today (Barc); 2019 Apr; 55(4):237-246. PubMed ID: 31050692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elagolix for endometriosis: all that glitters is not gold.
    Vercellini P; Viganò P; Barbara G; Buggio L; Somigliana E;
    Hum Reprod; 2019 Feb; 34(2):193-199. PubMed ID: 30551159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.
    Carr B; Dmowski WP; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
    Reprod Sci; 2014 Nov; 21(11):1341-51. PubMed ID: 25249568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elagolix (Orilissa)--an oral GnRH antagonist for endometriosis pain.
    Med Lett Drugs Ther; 2018 Sep; 60(1556):158-160. PubMed ID: 30383729
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
    Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
    N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elagolix as a Novel Treatment for Endometriosis-Related Pain.
    Fantasia HC
    Nurs Womens Health; 2019 Aug; 23(4):366-369. PubMed ID: 31276630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain.
    Taylor HS; Dun EC; Chwalisz K
    Pain Manag; 2019 Sep; 9(5):497-515. PubMed ID: 31434540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
    Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
    Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of SKI2670, a novel, orally active, non-peptide GnRH antagonist, on hypothalamic-pituitary-gonadal axis.
    Kim SM; Yoo T; Lee SY; Kim EJ; Lee SM; Lee MH; Han MY; Jung SH; Choi JH; Ryu KH; Kim HT
    Life Sci; 2015 Oct; 139():166-74. PubMed ID: 26321528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential role of elagolix for treating uterine bleeding associated to uterine myomas.
    Barra F; Vitale SG; Seca M; Scala C; Leone Roberti Maggiore U; Cianci A; Ferrero S
    Expert Opin Pharmacother; 2020 Aug; 21(12):1419-1430. PubMed ID: 32401547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
    Struthers RS; Nicholls AJ; Grundy J; Chen T; Jimenez R; Yen SS; Bozigian HP
    J Clin Endocrinol Metab; 2009 Feb; 94(2):545-51. PubMed ID: 19033369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.
    Shebley M; Polepally AR; Nader A; Ng JW; Winzenborg I; Klein CE; Noertersheuser P; Gibbs MA; Mostafa NM
    Clin Pharmacokinet; 2020 Mar; 59(3):297-309. PubMed ID: 31749075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Clinician's Guide to the Treatment of Endometriosis with Elagolix.
    Leyland N; Estes SJ; Lessey BA; Advincula AP; Taylor HS
    J Womens Health (Larchmt); 2021 Apr; 30(4):569-578. PubMed ID: 32975461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study.
    Diamond MP; Carr B; Dmowski WP; Koltun W; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
    Reprod Sci; 2014 Mar; 21(3):363-71. PubMed ID: 23885105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elagolix: First Global Approval.
    Lamb YN
    Drugs; 2018 Sep; 78(14):1501-1508. PubMed ID: 30194661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Conundrum: A 33-Year-Old With Pain Post-Orgasm and a History of Endometriosis.
    Yong PJ
    J Obstet Gynaecol Can; 2020 May; 42(5):625-628. PubMed ID: 32414477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.